On the other hand, intussusceptions that do not resolve

spontaneously and require intervention, whether by reduction under radiologic guidance or at surgery, which occur in the risk window after any dose of vaccine must be captured and provided rapid access to appropriate medical care. The World Health Organization’s guidance for post-marketing surveillance for rotavirus vaccines suggests a sentinel hospital approach where Z-VAD-FMK an estimate of the catchment area is possible [23]. Based on the data presented here, the WHO approach represents a feasible and pragmatic approach to identification of cases of intussusception, based on which studies on vaccine safety can be designed, but careful attention to data quality will be critical [24]. No authors have declared a conflict of interest “
“While rapid strides have been

made in child survival globally, the Millennium Development Goal of reducing child mortality by two thirds is unlikely to be achieved in developing countries where acute gastroenteritis and respiratory illnesses constitute the bulk of post neonatal under-five mortality [1]. The Integrated Global Action Plan for the Prevention and Control of Pneumonia and Diarrhea recommends the introduction of rotavirus vaccines in National Immunization Programs (NIP) along with scaling this website up other proven interventions to accelerate progress in child survival [2]. A liquid oral monovalent rotavirus vaccine (Rotavac), developed from the neonatal 116E mafosfamide rotavirus strain, a naturally occurring reassortant strain G9P [11], with one bovine gene, P[11], and 10 human rotavirus genes through an innovative partnership, is projected to cost about one

USD per dose and offers the prospect of an affordable rotavirus vaccine for the developing world. Since 1999 when a tetravalent rhesus reassortant rotavirus vaccine (Rotashield, Wyeth Laboratories) was withdrawn by its manufacturer on identification of excess risk of intussusception following immunization [3] and [4], the safety of newer rotavirus vaccines has received intense scrutiny in large licensure and post marketing studies. Currently licensed live rotavirus vaccines, Rotarix (GlaxoSmithKline Biologicals) and Rotateq (Merck), when evaluated in large phase III studies did not reveal any excess risk of intussusception [5] and [6]. However post-licensure studies with both these vaccines have identified a smaller safety signal with 1–5 excess cases of intussusceptions in 100,000 immunized infants in different parts of the world [4], [7], [8], [9] and [10] leading to the need to evaluate the risk of intussusception with other live rotavirus vaccines. Given the magnitude of risk seen with Rotarix and Rotateq, pre-licensure evaluation of a similar risk would require a trial size of several hundred thousand infants, making development of affordable vaccines difficult.